Abstract
Three criteria by which the appropriate host cell is chosen for the expression of a recombinant-derived vaccine antigen are efficacy, safety, and scale-up. Efficacy for a vaccine antigen refers to the ability of the host cell to produce a vaccine antigen capable of eliciting a protective immune response. A concern for safety of a vaccine antigen relates to residual DNA in the final product, especially when derived from continuous mammalian cell lines as opposed to microbial cells. Since tens (or hundreds) of millions of doses of a widely used vaccine might be injected into healthy infants and young children during the lifetime of the product, safety is a critical issue, such that the use of a microbial expression system might be preferable to the use of a continuous cell line in certain circumstances.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
